viewMedlab Clinical Ltd

MedLab Clinical plans European product expansion with wholly-owned subsidiary

Medlab Clinical Ltd (ASX:MDC) managing director & CEO Sean Hall speaks to Proactive Investors about the pharmaceutical company’s new European subsidiary and its development of products to treat chronic disease.

Medlab has 30 nutraceutical products (pharmaceutical-grade and standardised nutrients) globally, with another 10 in development, and two cannabis-based medicines NanaBis and NanaBidial which contain formulations of tetrahydrocannabinol and cannabidiol.

“There are financial advantages and concessions potentially available with the European Medicines Agency (EMA), if there is a European subsidiary,” Hall says.

He continues, “we are now exchanging paperwork with the EMA and trying to formalise what could be a significant discount on their drug registration fees moving forward, so that we can move beyond pathway development and actually formalising it with the regulatory agency for approved claims in Europe.”

Quick facts: Medlab Clinical Ltd


Price: 0.16 AUD

Market Cap: $54.75 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Medlab Clinical talks upcoming Phase III NanaBis trial and NanoCelle...

Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall tells Proactive's Andrew Scott they're focused on achieving regulatory approval for its lead drug candidate NanaBis™ in the shortest time possible. He adds that they've identified multiple revenue generating partnering opportunities for its NanoCelle®...

on 24/6/21

2 min read